Introduction
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that can be divided in at least two subsets based on the presence of antibodies to citrullinated proteins (ACPAs) [1] . Importantly, such ACPA target proteins [2] [3] [4] [5] also represent candidate autoantigens for CD4 + T cell responses, as further substantiated by the strong genetic association between ACPA-positive RA and the so called shared epitope HLA-DR alleles [6] [7] [8] . Indeed, previous studies of peripheral blood from ACPA-positive RA patients have demonstrated autoreactive CD4 + T cells against several citrullinated selfproteins [9-13] Alpha-enolase represents an interesting autoantigen in RA as the presence of autoantibodies against citrullinated -enolase is preferentially linked to HLA-DRB1*04 [14] , which is the most studied HLA class II allele in the context of RA. Although -enolase is considered a ubiquitous protein, it is citrullinated and overexpressed in the inflamed synovium [4] , and antibodies to the immunodominant citrullinated B cell epitope CEP-1 are present in approximately half of all ACPA-positive patients [14, 15] . These citrullinated -enolase-specific autoantibodies are highly specific for RA [4, 14] and significantly enriched in synovial fluid [16] . CD4 + T cells play an important role in RA by secreting pro-inflammatory cytokines and activating B cells, which contribute to the inflammatory perpetuation. A major technical hurdle, regarding the characterization of T cells that specifically recognize potential RA-specific autoantigens, is related to the fact that autoantigen-specific T cells are generally present in very low frequencies [17] [18] [19] [20] [21] . Through recent improvements in the field of HLA class II/peptide tetramers, based on bead enrichment, it is now possible to assess rare antigen-specific CD4 + T cells directly ex vivo without prior in vitro expansion [13, [22] [23] [24] .
Furthermore, several T cell epitopes have been identified based on the notion that the P4 pocket of RA-associated HLA-DR alleles cannot accommodate a positively charged arginine side chain but can fit a neutral citrulline [25] .
However, a growing list of citrulline-specific T cell epitopes have demonstrated that the citrulline can also be located in positions contributing to TCR contact [13, 26, 27] . We have recently scanned the entire -enolase protein for T cell epitopes and demonstrated the existence of several peptides for which the citrulline modification is not confined to the classical P4 position in the HLA binding cleft [26] . Since this alternative repertoire of T cell epitopes has been less studied, we have here focused on the -enolase peptide KRIAKAVNEKSCNCL, spanning residue 326 to 340 which comprises an arginine residue at the N-terminus. We have previously demonstrated the suitability of this epitope for HLA-tetramer studies aiming at characterization of specific autoreactive T cell populations [13] . Moreover, we have demonstrated in peptide competition assays that both peptide versions, native eno326-340 and modified cit-eno326-340 have similar binding affinities to HLA-DRB1*04:01 [26] .
This provided us with a unique opportunity to assess the contribution of the non-conventionally located arginine/citrulline residue of the peptide to T cell receptor (TCR) recognition. To achieve this, we determined the crystal structures of the HLA-DRB1*04:01/eno326-340 and HLA-DRB1*04:01/cit-eno326-340 complexes at 1.33Å and 1.35Å resolution, respectively, and demonstrated the existence of both specific as well as cross-reactive T cells. Strikingly, only cit--eno326-340 specific T cells were found to be enriched in the RA joint implicating their involvement in the HLA-restricted immune response driving joint inflammation.
Material and methods

Patients and healthy control subjects
RA patients (n=38) were recruited under the auspices of the Karolinska University Hospital Rheumatology clinic, the BRI rheumatic disease registry and the BRI immune-mediated disease registry and had an age range of with 84% being CCP-positive. Control subjects (n=15) were recruited from the BRI IMD registry and the Uppsala Bioresource and had an age range of 27-82.
Informed consent was obtained from all patients and control subjects based on local ethical permits. All patients were diagnosed with RA by a rheumatologist in accordance with the 1987 American College of Rheumatology criteria [28] .
All subjects had at least one copy of the HLA-DRB1*04:01 allele. Peripheral blood mononuclear cells (PBMC), obtained from heparinized blood and synovial fluid mononuclear cells (SFMC), were prepared by centrifugation over Ficoll-Hypaque gradients. Frozen samples were cryopreserved in liquid nitrogen in 10% DMSO and 90% heat-inactivated FBS. Frozen samples were utilized for studies carried out at KI and fresh samples were used for all analyses carried out at BRI. Synovial biopsies were obtained through ultrasound-guided arthroscopy from two HLA-DRB1*04:01 RA patients. The synovial tissues were digested via incubation with Collagenase A and DNAse I (Roche).
Production of HLA-DRB1*04:01/peptide tetramers
Recombinant HLA-DRB1*04:01/peptide complexes were produced as previously described [29] . All peptides were purchased at purity higher than 95% from GenScript, Inc. Biotinylated HLA-DRB1*04:01 monomers were loaded with either the influenza-hemagglutinin HA306-318, the native or the citrullinated versions of the -enolase peptide eno326-340 by incubation in the presence of n-octyl--D-glucopyranoside and Pefabloc SC (Sigma-Aldrich).
Peptide-loaded monomers were subsequently conjugated to tetramers using either R-PE streptavidin (Invitrogen) or APC streptavidin (BD).
In vitro detection of native and citrullinated -enolase-specific T cells using
HLA class II tetramers
For tetramer assays PBMCs from healthy controls or synovial biopsies (n=2) from DRB1*04:01 RA subjects were cultured in RPMI-1640 + 10% pooled human serum with 10g/ml of HA306-318, native or citrullinated eno326-340 peptides. Interleukin-2 (IL-2) (Proleukin, Novartis) was added on day 6. After 14 days, cells were stained according to table S1. Data was analyzed using FlowJo software (Treestar).
Ex vivo detection of native and citrullinated -enolase-specific T cells using
HLA class II tetramers
PBMC and SFMC samples from RA patients were labeled according to table S1 as previously described [29] . Samples were run on a BD-LSRII flow cytometer or a Beckman Coulter Gallios, and data was analyzed using FlowJo software. The frequency of antigen-specific cells was calculated as the total number of tetramer-positive cells in the bound fraction divided by the total number of CD4 + T cells. A cut-off of 1/10 6 CD4 + T cells was applied.
Murine Assays
HLA-DRB1*04:01-IE transgenic mice on a class II deficient C57Bl/6 (I-Abo/o) background were obtained from Taconic Biosciences (Hudson, NY, USA) and housed under specific pathogen-free conditions. Mice were immunized with 100g of peptide, and splenocytes, harvested at day 14, were used for studying recall responses as previously reported [13] . All animal work was approved by the BRI Animal Care and Use Committee (ACUC). Animals were housed in the BRI AAALAC-accredited animal facility. complexes were concentrated to 1mg/ml in 25mM Tris-HCl (pH8) and subjected to thrombin cleavage in order to remove the leucine zippers. The HLA/peptide complexes were thereafter separated from leucine zippers using a HiTrap Chelating HP column (GE Healthcare). The flow-through from IMAC was pooled, concentrated using a Vivaspin (Sartorius) to 2-3mg/ml and further purified on a Superdex200-10/300 GL column. Fractions containing monomeric HLA/peptide complexes were concentrated to a final concentration of 6-8mg/ml and used in crystallization trials.
Production and isolation
Crystallization and structure determination
Crystals of the HLA-DRB1*04:01/eno326-340 and HLA-DRB1*04:01/cit-eno326-340 complexes were grown using the hanging-drop vapor diffusion method at 20°C.
Protein solution and a mother liquor of 10% (vol/vol) MPD, 15% (vol/vol) PEG3350 and 100mM MES buffer pH6.5 were mixed at a 1:1 ratio. Rod-like crystals typically grew within five to fifteen days. Crystals were flash frozen in liquid nitrogen without additional cryoprotection. X-ray diffraction data from a single crystal for each data set were collected at the automatic ID30A-1 (MASSIF-1) beam line [30] at the European Synchrotron Research Facility and processed using the programs XDS [31] and XDSAPP [32] . The crystals diffract up to 1.33Å and 1.35Å for HLA-DRB1*04:01/eno326-340 and HLA-DRB1*04:01/cit-eno326-340, respectively. The crystal structures were determined by molecular replacement method using the program Phaser [33] with the three-dimensional structure of HLA-DRB1*04:01 (PDB ID:4MCY) [34] without peptide as a search model. The models were subsequently refined using Refmac5 and iterations of manual rebuilding using COOT [35] (Table 1 ). The structures were validated using MOLPROBITY [36] . The atomic coordinates and structure factors for the crystal structures of the HLA-DRB1*04:01 in complex with eno326-340 and cit-eno326-340 have been deposited to the Protein Data Bank under accession codes 5NI9 and 5NIG, respectively.
Statistics
Statistical tests used for this paper include Wilcoxon matched pairs ranked test and Mann-Whitney tests. Analyses were performed using Prism software (version 5.0 or higher). Values <0.05 were considered as significant and marked with an asterisk. Two asterisks denote values <0.01.
Results
The crystal structures of HLA-DRB1*04:01 in complex with eno326-340 and cit-eno326-340 reveal conserved peptide binding registry and conformation
The crystal structures of HLA-DRB1*04:01/eno326-340 and HLA-DRB1*04:01/citeno326-340 complexes were refined to 1.33Å and 1.35Å resolution, respectively The crystal structures of HLA-DRB1*04:01/eno326-340 and HLA-DRB1*04:01/citeno326-340 complexes revealed two interesting additional features. First, residue p334E forms two interactions with "shared epitope" residues in HLA-DRB1*04:01, including a salt bridge with K71B and a water-mediated hydrogen bond with Q70B (suppl figure 2). These interactions possibly compensate for the relatively weak binding of the non-optimal peptide anchor residues p331A and p336S to pockets P4 and P9, respectively. Secondly, the two crystal structures are to our knowledge the first to describe the presence of a disulfide bridge between peptide cysteine residues. It is not clear if the disulfide bridge between p337C and p339C has any functional consequence although a mutated version of the eno326-340 peptide, with both cysteine residues replaced to serine, displays one order of magnitude lower affinity towards HLA-DRB1*04:01 compared to native eno326-340 (supplementary figure 3).
Use of peptide-HLA-DRB1*04:01 tetramers for visualization of antigenspecific CD4 + T cells in vitro and ex vivo
Before utilizing peptide-HLA tetramers for ex vivo assessment of autoreactive T cells in RA patient samples, we first validated our reagents by use of peripheral blood from healthy blood donors carrying the same HLA-DR allele.
As shown in figure 2A , both influenza-HA-and -eno326-340-specific T cells can be readily visualized following 2 weeks in vitro propagation with the corresponding peptide. The HLA tetramers were also successfully used for direct ex vivo staining, i.e. without any prior in vitro cell manipulation. As exemplified in figure 2B , influenza-HA specific T cells could, as expected, be detected in RA synovial fluid. In this particular example, the antigen-specific cells could be enumerated to 20 per million CD4 + T cells, and based on the phenotypic markers, the proportion of tetramer-positive cells being of memory CD45RO + phenotype could be determined (here 85%), as well as additional phenotypic markers (0% CD25+ and 100% CD28+).
CD4 + T cells recognizing the native -enolase326-340 peptide in complex with
HLA-DRB1*04:01 are part of the normal T cell repertoire but mostly display a naïve phenotype
We next continued with ex vivo staining using HLA tetramers assembled with either the positive control influenza-HA peptide or with the native argininecontaining eno326-340 peptide. Both T cell specificities were found to be part of the peripheral T cell repertoire of both healthy donors and RA patients carrying the HLA-DRB1*04:01 allele ( figure 2C, D) . For HA, all healthy controls and all RA subjects displayed influenza-specific T cells with an average of 26 per million CD4 + cells in each group. In contrast, -eno326-340-specific T cells were more rare and only detected in around 66% of RA patients with an average of 4 per million CD4 + , and 2 per million in healthy individuals. When it comes to the phenotype of this autoantigen-specific T cell population, it was distinctly different from HA-specific T cells which in both healthy subjects and RA patients were primarily (80%) CD45RO + memory. The T cells recognizing the native version of eno326-340 were mostly naïve with only 20% memory in peripheral blood of both healthy donors and RA patients (figure 2E). Lastly, we had the possibility to assess Tmr+ T cells in paired samples of peripheral blood and synovial fluid taken from the same patients. Here we found that, in four out of seven paired samples, the numbers of native eno326-340 specific T cells are increased in SF compared to PB when gating at the CD45RO+ population. For cit-eno326-340 specific T cells, an increase was only seen in two out of six sample pairs, but when present, the frequency was much higher than those for the native peptide (figure 3E).
CD4 + T cells recognizing the citrullinated
Presence of both specific and cross-reactive T cells recognizing native and citrullinated eno326-340
Our crystal structures of HLA-DRB1*04:01 in complex with eno326-340 or citeno326-340 indicated that dependent on where the TCR docks, T cells could either be specific for the respective peptides (by binding to the N-terminal part of the peptide-HLA complex) or cross-react (when interacting with the central parts of the peptide-HLA complexes). To visualize this, we overlayed our crystal structure of HLA-DRB1*04:01/eno326-340 with three ternary complexes with known three-dimensional structures: HLA-DRB1*04:01 with a TCR specific for a viral peptide [37] , a tumor-specific TCR [38] and a TCR specific for the multiple sclerosis-associated autoantigen myelin basic protein [39] (figure 4).
The superposition clearly demonstrates that peptide residue p327R could interact with the -chain of a TCR. Since this residue protrudes away from the HLA molecule, its conformation can change after TCR binding resulting in interaction either with CDR3 or with CDR1. Modeling of the interaction surface area found in three crystal structures of ternary complexes DRB1*0401/TCR [37] clearly demonstrates that in all cases TCR come close to the amino acid preceding the first anchor residue (Figure 4a and b) . . These results implicate that the -enolase-specific T cells we detect with tetramers represent a diverse repertoire with some being dependent on interactions with the N-terminal arginine/citrulline residues, and others not.
As a next step, we immunized HLA-DRB1*04:01-IE transgenic mice with the native eno326-340 peptide and examined recall responses to both the native and citrullinated versions of the -enolase peptide. Mice immunized with eno326-340 displayed similar proliferation responses irrespective if they were re-stimulated with eno326-340 or cit-eno326-340 (figure 5C), suggesting high degree of T cell cross-reactivity between the two peptides in a setting of active immunization.
As we previously reported, the opposite observation is also true, i.e. mice immunized with cit-eno326-340 displayed recall responses to both versions of the peptide [13] . [40, 41] or in the lungs [8, 42, 43] . These memory T cells may subsequently migrate to the joints in response to some 'local insult' [44] , where they may be reactivated since extracellular citrullination is abundant during any kind of inflammation. These effector memory T cells may then contribute to the maintenance of an inflammatory milieu.
Moreover, our structural data allow the dissection of cross-reactivity and the possibility to predict TCR interactions. The vast majority of crystal structures of ternary TCR-peptide-HLA class II complexes indicate that the -chain of the TCR is landing in the vicinity of the first anchor residue [37] [38] [39] Obviously, there are some limitations in our study; due to sample constraints, we had to focus our efforts on one specific T cell epitope from one candidate autoantigen. Optimally, we could have studied several different peptides in parallel. Additionally, all RA patients included in the study have a chronic disease, and all of them are immunosuppressed, which could affect the observed frequency and functionality of their T cells [13] . However, our cohort is representative for real life scenario patients. In fact, our data on peripheral blood are in good agreement with other studies using both in vitro and ex vivo approaches [13, 48] . Our results using synovial fluid cells, furthermore, corroborate the findings from the borrelia-induced Lyme arthritis, showing higher frequency of antigen-(borrelia)-reactive T cells in synovial fluid compared to peripheral blood [49, 50] .
Conclusions
We identified and characterized autoreactive CD4 + T cells specific for HLA-DRB1*04:01 in complex with the RA autoantigen -enolase-derived native eno326-340 and citrullinated cit-eno326-340 peptides in the periphery, synovial fluids and synovial tissues of RA patients. Importantly, citrulline--enolasespecific T cells were more often of a memory phenotype in the circulation and were enriched in the synovial fluid compared to those recognizing the native variant of the peptide. This study highlights the added value of interrogating the inflamed joint and not only peripheral blood when studying autoimmunity.
Suppl Table 1 Values in parentheses are for the highest resolution shell 1 redundancy independent R-factor (intensities) [36] 2 Rcryst = Σ||Fo| -|Fc||/Σ|Fo|, where |Fo| and |Fc| are the observed and calculated structure factor amplitudes of a particular reflection and the summation is over 95% of the reflections in the specified resolution range. The remaining ~5% of the reflections were randomly selected (test set) before the structure refinement and not included in the structure refinement. 3 Rfree was calculated over these reflections using the same equation as for Rcryst. Increasing concentrations of the peptides were incubated in 384-well polypropylene plate in the presence of 30nM HLA-DRB1*04:01 and 5nM biotin-labeled HA306-318 peptide overnight at 37C in a humidified incubator.
Reaction mixture was transferred to a polystyrene plate coated with anti-HLA-DR mAb L243 and incubated overnight at +4C. Bound peptide-HLA complexes were developed in DELFIA time-resolved fluorescence assay using europium-labeled streptavidin (PerkinElmer).
